Company Analysis
Sign in

Precigen, Inc. (PGEN)

Nasdaq: PGEN · Pharmaceutical Preparations · Germantown, MD · filing with the SEC since 2006
Full chart Alerts Compare
Grade3.8
◀ Past 3.2● Present 4.0▶ Future 4.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

181 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Precigen, Inc.’s names, not what it holds today.

Patents granted
181
181 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 9 in 2024 and 8 in 2023
Applications published
211
5 of them in 2025
Names they are printed under
7
a former name, its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology23
Pharmaceuticals13
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
INTREXON CORPORATION a former name
US, as the owner printed on each patent
122 granted
98 published
Precigen, Inc. its own name
US, as the owner printed on each patent
29 granted
29 published
Intrexon Corporation a former name
named as the applicant on its applications, in US
0 granted
50 published
INTREXON ACTOBIOTICS N.V. a subsidiary
BE, as the owner printed on each patent
27 granted
15 published
PRECIGEN, INC. its own name
named as the applicant on its applications, in US
0 granted
9 published
EXEMPLAR GENETICS LLC a subsidiary
US, as the owner printed on each patent
3 granted
4 published
INTREXON ACTOBIOTICS NV a subsidiary
named as the applicant on its applications, in BE
0 granted
6 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,404,306Human papillomavirus vaccines and uses of the samePharmaceuticalsPrecigen, Inc.
Jul 15, 202512,359,210Genetically modified bacteria stably expressing IL-10 and insulinBiotechnologyINTREXON ACTOBIOTICS N.V.
Apr 15, 202512,275,772ROR-1 specific chimeric antigen receptors and uses thereofBiotechnologyPrecigen, Inc.
Mar 18, 202512,252,516Mucoadhesive microorganismPharmaceuticalsINTREXON ACTOBIOTICS N.V.
Mar 11, 202512,246,046Compositions and methods for the treatment of type 1 diabetesPharmaceuticalsINTREXON ACTOBIOTICS N.V.
Feb 25, 202512,234,465Methods and microorganisms for the fermentation of methane to multi-carbon compoundsBiotechnologyPrecigen, Inc.
Feb 25, 202512,234,261Hepatitis B vaccines and uses of the samePharmaceuticalsPrecigen, Inc.
Jan 14, 202512,194,094Fusion constructs and methods of using thereofBiotechnologyPrecigen, Inc.
Dec 31, 202412,180,517Expression of novel cell tagsBiotechnologyPrecigen, Inc.
Sep 17, 202412,091,667Molecular switchesBiotechnologyPrecigen, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388905POLYCISTRONIC miRNA CONSTRUCTS FOR IMMUNE CHECKPOINT INHIBITIONBiotechnologyPRECIGEN, INC.
Oct 23, 20252025/0325665FUSION CONSTRUCTS AND METHODS OF USING THEREOFBiotechnologyPrecigen, Inc.
Oct 2, 20252025/0304930EXPRESSION OF NOVEL CELL TAGSBiotechnologyPrecigen, Inc.
Jul 10, 20252025/0223320HEPATITIS B VACCINES AND USES OF THE SAMEPharmaceuticalsPrecigen, Inc.
Jan 23, 20252025/0027093MOLECULAR SWITCHESBiotechnologyPrecigen, Inc.
Dec 5, 20242024/0398926NOVEL ADENOVIRUS VACCINE THERAPY FOR THE TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSISPharmaceuticalsPrecigen, Inc.
Nov 28, 20242024/0390475HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAMEPharmaceuticalsPrecigen, Inc.
Nov 7, 20242024/0368638Biological Production of Multi-Carbon Compounds from MethaneBiotechnologyPRECIGEN, INC.
Nov 7, 20242024/0368637METHODS AND MICROORGANISMS FOR MAKING 1,4-BUTANEDIOL AND DERIVATIVES THEREOF FROM C1 CARBONSBiotechnologyPrecigen, Inc.
Nov 7, 20242024/0368305MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFBiotechnologyPrecigen, Inc.
What it applied for, 2024 to 2025: Biotechnology 11 · Pharmaceuticals 6 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PGEN · research, not advice